U.S Appeals Court Lifts Injunction Against Hanmi’s Modified Nexium Generic – AstraZeneca
This article was originally published in PharmAsia News
U.K. drug maker AstraZeneca said a U.S. federal appeals court has lifted an injunction against Hanmi Pharmaceutical Co. Ltd. launching Esomezol, an incrementally modified generic of its blockbuster Nexium (esomeprazole).
You may also be interested in...
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.